A Real-world Chronic Myelogenous Leukemia (CML) Patient Disease Registry to Describe Patient Experience and Clinical Outcomes Among Patients With CML Receiving Approved First or Second Line Tyrosine Kinase Inhibitor (TKI) Therapy (NCT07091019)
🩺 Plain-English Summary (8th-Grade Level)
This CML disease registry (ASC4REAL-2) aims to gather evidence on the tolerability, safety, effectiveness, and patient-reported outcomes (PRO) in real-world healthcare from patients with Ph+-CML-CP treated with TKIs approved for 1L and 2L, including prospective follow-up for 5 years identifying and describing long-term treatment outcomes.
Who can join: Review the eligibility criteria below.
Location: University of Alabama at Birmingham — Birmingham, Alabama
Age range: 18 Years to 100 Years
🧪 Interventions in This Study
- TKIs (OTHER)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (17 Sites)
- University of Alabama at Birmingham — Birmingham, Alabama
- Stockton Hematology Oncology Medical Group Inc — Stockton, California
- Lundquist Inst BioMed at Harbor — Torrance, California
- Stamford Hospital — Stamford, Connecticut
- Sacred Heart Medical Oncology — Pensacola, Florida
- Cancer Care Specialists of Central Illinois — Decatur, Illinois
- St Agnes Hospital — Baltimore, Maryland
- Truman Medical Center — Kansas City, Missouri
- NY Cancer and Blood Specialists — East Setauket, New York
- SUNY Upstate Medical University — Syracuse, New York
- Tri-County Hematology and Oncology Associates — Canton, Ohio
- Oregon Oncology Specialists Salem — Salem, Oregon
- Avera Cancer — Sioux Falls, South Dakota
- Baylor Scott and White Research — Temple, Texas
- Fred Hutchinson Cancer Research Center — Seattle, Washington
- MultiCare Health System Institute — Tacoma, Washington
- Northwest Medical Specialties — Tacoma, Washington
📞 Contact the Study Coordinator
Phone: (888) 669-6682
Email: novartis.email@novartis.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Chronic Myelogenous Leukemia - Chronic Phase
Explore by condition: All Chronic Myelogenous Leukemia - Chronic Phase clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.